Evidence map›Paper›PMID 24695516›Full record

ArticlePloS one2014

Evolutionary origins of C-terminal (GPP)n 3-hydroxyproline formation in vertebrate tendon collagen.

David M Hudson, Rachel Werther, MaryAnn Weis, Jiann-Jiu Wu, David R Eyre

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Collagen IV biosynthesis: Intracellular choreography of post-translational modifications.Matrix biology : journal of the International Society for Matrix Biology · 2025
    Review
  3. Loss of the long form of Plod2 phenocopies contractures of Bruck syndrome-osteogenesis imperfecta.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2024
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

David M HudsonDepartment of Orthopaedics and Sports Medicine, University of Washington, Seattle, Washington, United States of America.
Rachel WertherDepartment of Orthopaedics and Sports Medicine, University of Washington, Seattle, Washington, United States of America.
MaryAnn WeisDepartment of Orthopaedics and Sports Medicine, University of Washington, Seattle, Washington, United States of America.
Jiann-Jiu WuDepartment of Orthopaedics and Sports Medicine, University of Washington, Seattle, Washington, United States of America.
David R EyreDepartment of Orthopaedics and Sports Medicine, University of Washington, Seattle, Washington, United States of America.
University of Washington · US

Funding

Project 3: Collagen post-translational modification and cross-linking in OIP01HD070394 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI LEE, BRENDAN · 2011 to 2020
$13.4M
Collagen Cross-linking in Skeletal Aging and DiseaseR37AR037318 · NIAMS · UNIVERSITY OF WASHINGTON · PI EYRE, DAVID R · 2010 to 2019
$3.4M
PATHOLOGY OF INBORN SKELETAL DISEASESR01AR037318 · NIAMS · UNIVERSITY OF WASHINGTON · PI EYRE, DAVID R · 1986 to 2009
$3.4M
Collagens of Cartilage and the Intervertebral DiscR01AR036794 · NIAMS · UNIVERSITY OF WASHINGTON · PI EYRE, DAVID R · 1986 to 2014
$3.3M
NIAMS NIH HHS AR37318NIAMS NIH HHS AR37694NIAMS NIH HHS R01 AR036794NIAMS NIH HHS R01 AR037318NIAMS NIH HHS R37 AR037318NICHD NIH HHS P01 HD070394
6 · The paper itself

Abstract

Approximately half the proline residues in fibrillar collagen are hydroxylated. The predominant form is 4-hydroxyproline, which helps fold and stabilize the triple helix. A minor form, 3-hydroxyproline, still has no clear function. Using peptide mass spectrometry, we recently revealed several previously unknown molecular sites of 3-hydroxyproline in fibrillar collagen chains. In fibril-forming A-clade collagen chains, four new partially occupied 3-hydroxyproline sites were found (A2, A3, A4 and (GPP)n) in addition to the fully occupied A1 site at Pro986. The C-terminal (GPP)n motif has five consecutive GPP triplets in α1(I), four in α2(I) and three in α1(II), all subject to 3-hydroxylation. The evolutionary origins of this substrate sequence were investigated by surveying the pattern of its 3-hydroxyproline occupancy from early chordates through amphibians, birds and mammals. Different tissue sources of type I collagen (tendon, bone and skin) and type II collagen (cartilage and notochord) were examined by mass spectrometry. The (GPP)n domain was found to be a major substrate for 3-hydroxylation only in vertebrate fibrillar collagens. In higher vertebrates (mouse, bovine and human), up to five 3-hydroxyproline residues per (GPP)n motif were found in α1(I) and four in α2(I), with an average of two residues per chain. In vertebrate type I collagen the modification exhibited clear tissue specificity, with 3-hydroxyproline prominent only in tendon. The occupancy also showed developmental changes in Achilles tendon, with increasing 3-hydroxyproline levels with age. The biological significance is unclear but the level of 3-hydroxylation at the (GPP)n site appears to have increased as tendons evolved and shows both tendon type and developmental variations within a species.

Indexed as

Amino Acid SequenceAnimalsBone and BonesCattleChickensCollagen Type ICollagen Type IIEvolution, MolecularFibrillar CollagensHumansHydroxylationHydroxyprolineLampreysProtein Structure, TertiaryTendonsVertebrates3-hydroxyprolineCollagen Type ICollagen Type IIFibrillar CollagensHydroxyproline

Identifiers

PMID24695516
PMCPMC3973637
OpenAlexW2083161874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.